We suggest that combination of these biomarkers with more specific, ALS-linked biomarkers such as TDP-43 in the CSF (as also suggested by Bourbouli, et al. [31]) will tremendously improve the clinical management of ALS patients. Here, TARDBP is linked to amyotrophic lateral sclerosis.